Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

Inclusion Criteria: * Patient must have cholangiocarcinoma, gallbladder cancer or adenocarcinoma on liver biopsy with clinical features consistent with biliary primary/cholangiocarcinoma * Metastatic or unresectable disease documented on diagnostic imaging studies * Must have received at least one regimen containing gemcitabine chemotherapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 * Total bilirubin =\< 1.5 mg/dL (25.65 mol/L) * Aspartate transaminase (AST) and alanine transaminase (ALT) =\< 3.0 times the upper limit of normal (\[ULN\]; or 5.0 times the ULN in the setting of liver metastases) * Absolute neutrophil count (ANC) \>= 1000/uL * Hemoglobin \>= 9 g/dL (5.58 mmol/L) * Platelets \>= 100,000/uL * The patient does not have: * Cirrhosis at a level of Child-Pugh B (or worse) or * Cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis; clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis * Serum creatinine =\< 1.5 times the ULN or * Creatinine clearance (measured via 24-hour urine collection) \>= 40 mL/minute (that is, if serum creatinine is \> 1.5 times the ULN, a 24-hour urine collection to calculate creatinine clearance must be performed * The patient's urinary protein is =\< 1 positive (+) (=\< 30-100 mg/dl) on dipstick or routine urinalysis (urinary analysis \[UA\]; if urine dipstick or routine analysis is \>= 2+ (\>=…